Paul Hudson, AP Images

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

As part of CEO Paul Hud­son’s mis­sion to re­vamp the com­pa­ny’s strat­e­gy around on­col­o­gy and im­munol­o­gy R&D, Sanofi un­wrapped plans in Feb­ru­ary to hive off its lega­cy API busi­ness. But Sanofi wants to main­tain its EU her­itage for the new com­pa­ny, and now has a name and new leader to move the spin­off ahead.

Sanofi will name its ac­tive phar­ma­ceu­ti­cal in­gre­di­ents spin­off Eu­roAPI, a nod to the com­pa­ny’s roots in the EU and planned op­er­a­tions home base for what will be the sec­ond largest in­gre­di­ents pro­duc­er in the world, Sanofi said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.